Sentences with phrase «treatment therapy for»

Treatment therapy for cardiomyopathies often includes devices implantation, such as pacemakers, to regulate blood flow within the heart.

Build & test your knowledge about deprescribing opioids, treating acute before it becomes chronic pain, and pain treatment therapies for different conditions.

Build and test your knowledge about deprescribing opioids, treating acute before it becomes chronic pain, and pain treatment therapies for different conditions.

Diagnosing, Staging and Treating Cancer Talking To Your Vet about Your Pet Choosing the Best Veterinarian for Your Dog's Care Things to Remember At the Office Visit Getting a Second Opinion 3rd Party Test Results Choosing Your Dogs Medical Team Creating a Treatment Plan Dog Cancer Treatments Complete Cancer Removal Partial Removal of the Cancer: Debulking Exploratory Surgery Recovery from Surgery Follow - Up Care Chemo Radiation Vitamins & Antioxidants Immunostimulants Anti-Cancer Herbs Other Dietary Supplements Barf Ingredients Building a Strong Immune System: Cancer Is an Immune System Disease The Immune System as a Natural Defense against Cancer and Its Recurrence Restoring Immune Recognition Response with Supplements Immune Support for Effects of Chemo, Radiation and Treatment Drugs Quality Of Life for the Time Left with Your Dog Holistic Treatment Therapies for Canine Cancer Homeopathic Remedies Enhancing Conventional Treatment with Supplements Herbs, Vitamins and Supplements Immune Enhancing Supplements Immune Enhancing Herbal Products Healing Touch The Diet That Can Save Your Dogs Life: What You Should Feed Your Dog Vegetarian Homemade Dog Food Diets What Does Commercial Pet Food Really Contain?

Not exact matches

Furthermore, an early - stage study pumping up the dose of its hemophilia A treatment — which aims to be a one - time therapy for the rare blood clotting - related disease — appeared to hit its targets without serious side effects.

Then colchicine, which has unusual anti-inflammatory properties, proved effective as a treatment for gout, and eventually became a second - line therapy for pericarditis.

Spark Therapeutics» stock soared 20 % in Wednesday trading on the heels of its second quarter 2017 earnings report and some (very) early data on the gene therapy - focused firm's treatment for the blood disorder hemophilia A.

But the initiative comes with another huge financial prize for firms that successfully win FDA approval for these niche therapies: a priority review voucher that can be used to slash the regulatory period for a different experimental specialty treatment being developed by a drug maker or, more often, sold for potentially hundreds of millions of dollars to another pharma company.

A panel of experts which advises the Food and Drug Administration (FDA) has unanimously voted to recommend approval of a pioneering cancer therapy from Novartis, setting up a likely approval for the first - of - its - kind treatment.

The facility used straight jackets, electroshock therapy, and lobotomies as methods of treatment for mental illnesses.

The treatment, named Kymriah, was hailed by doctors and the life sciences community as a major advance in medicine and a boon to children and young adults with a certain form of leukemia (the group for whom the gene therapy is approved).

As a result, phage therapy is now used only for the sickest patients, as a treatment of last resort.

Psychologists and other medical professionals are using VR to heighten traditional therapy methods and find effective solutions for treatments of PTSD, anxiety and social disorders.

Insurers like Anthem have refused to cover the exorbitantly pricey treatment (around $ 300,000) since the drug's label admits that Exondys hasn't proved its efficacy, making the therapy a roll of the dice for payers and patients alike.

Another recently approved one - time therapy, Novartis» Kymriah for a form of leukemia, also has an outcomes - based pledge: If the treatment isn't working after a month, Novartis doesn't get paid.

The first gene therapy in the U.S. now has a price tag: $ 850,000 for the one - time treatment, or, more specifically, $ 425,000 per eye for a retinal disorder.

The treatment was approved for the devastating rare disease Duchenne muscular dystrophy but created major divisions within the FDA because it simply hadn't demonstrated a whole lot of efficacy, meaning the pricey therapy is essentially being subjected to a real - world clinical test.

The treatment is delivered just once, a facet of gene therapy that poses unique pricing questions in an industry fueled by steady payments for chronic therapies.

For instance, just last month, the Food and Drug Administration (FDA) approved ViiV's Juluca, the first - ever treatment for HIV - 1 that contains just two drugs (rather than the three or more involved in most HIV therapy cocktailFor instance, just last month, the Food and Drug Administration (FDA) approved ViiV's Juluca, the first - ever treatment for HIV - 1 that contains just two drugs (rather than the three or more involved in most HIV therapy cocktailfor HIV - 1 that contains just two drugs (rather than the three or more involved in most HIV therapy cocktails).

But for all of the attention paid to its cancer drug pipeline, Bristol just scored a breakthrough therapy designation from the Food and Drug Administration for a treatment that targets hepatitis C.

This is the second high - profile therapy to test out the fledgling pay - for - performance model in the U.S. behind Novartis» blood cancer treatment Kymriah.

Approved treatments included gene therapies and the first new drugs for rare diseases in many years.

«Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important way to help spur competition that can lower healthcare costs and increase access to important therapies,» said FDA Commissioner Scott Gottlieb in a statement.

Gilead subsidiary Kite Pharma (which the biotech giant scooped up ahead of the FDA's approval for Yescarta, a treatment that reengineers patients» immune cells to fight cancer) will have access to Sangamo's platform technology, which could be used to create various types of cancer cell therapies.

About Nohla Therapeutics Nohla Therapeutics is a leading developer of off - the shelf cell therapies for the treatment of cancer and other critical diseases.

And there have been developments in cellular therapies to treat cancer, with two treatments aiming for approval by the end of 2017.

On Wednesday, the U.S. Food and Drug Administration approved Novartis» Kymriah, the first drug for a new kind of cancer treatment called CAR - T cell therapy.

Bellicum is among the flurry of biotechs investing heavily into cell therapies such as experimental chimeric antigen receptor T - cell (CAR - T) treatments for cancer (this is the next - gen treatment that involves reprogramming immune cells to become cancer killers and has shown promise in blood cancers, which Bellicum specializes in).

Though it's not a perfect treatment, Eli Lilly's solanezumab — a drug 15 years in the making — will pass muster in clinical tests and be well on its way to FDA approval, as a therapy for mild Alzheimer's, by year's end.

And a third, different kind of gene therapy from Spark Therapeutics — to treat a rare inherited form of blindness — is likely to be approved by the end of 2017, too, making this year a landmark for treatments that manipulate the body's own biological mechanisms in novel new ways to fight deadly diseases.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

«Precision medicine is already positively affecting providers (for example, by reducing ED visits by 30 % through application of molecular profiling treatment strategy); payers ($ 25 billion expected annual spending on genetic tests by 2021, and 45 % of FDA approvals were geared toward targeted therapies in 2013); and pharma (the pharmacogenomics market is expected to be $ 7.5 billion by 2017).»

Samsung Bioepis, which has a pipeline of these kinds of copycat treatments for a number of flagship therapies, specifically cited the price - cutting potential of biosimilars.

«Based on the results from these Phase 3 studies, the combination of bictegravir and FTC / TAF could represent an important advance in triple - therapy treatment for a broad range of HIV patients, and we look forward to submitting regulatory applications in the U.S. and EU this year.»

Antiretroviral therapy has turned HIV from a death sentence into a manageable condition but patients need to stay on the treatment for life, so there is a growing focus on making medication as convenient and well - tolerated as possible.

Retrophin is a publicly - held biopharmaceutical company focused on the development of therapies for the treatment of serious, catastrophic, or rare diseases.

Accelerator Life Science Partners launched a spinoff company to develop an investigational migraine treatment into a therapy for a variety of seizure disorders and landed...

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.

On April 23rd they announced receipt of the FDA's RMAT (Regenerative Medicine Advanced Therapy) designation for ABO - 102 for the treatment of Sanfilippo syndrome Type A (MPS IIIA).

Novartis set the price for the one - time treatment at $ 475,000, right in line with low - end estimates and one that will put pressure on Gilead to rein in its own price for a rival therapy expected to be approved in the near future.

Abeona Therapeutics announced receipt of the FDA's RMAT (Regenerative Medicine Advanced Therapy) designation for ABO - 102 for the treatment of Sanfilippo syndrome Type A.

Second, Darzalex secured an important FDA label expansion last year for its use as a second - line multiple myeloma treatment rather than only as a third - line therapy.

Katherine High, Spark's president and chief scientific officer, expressed her enthusiasm for the early clinical data related to SPK - 8011: «The encouraging start of our SPK - 8011 clinical trial reinforces the strength of our gene therapy platform, delivers human proof - of - concept in a second liver - mediated disease — a significant achievement in the gene therapy field — and positions us well to potentially transform the current treatment approach for this life - altering disease with a one - time intervention.»

Shares of Exelixis, Inc. (NASDAQ: EXEL) were trading higher by 20 percent early Monday morning after the company announced an encouraging update for its CABOMETYX (cabozantinib) therapy for the treatment of patients with advanced hepatocellular carcinoma.

The family couldn't find chemo therapy treatments in Venezuela due to severe medical shortages, so Beke's relatives had to send the medicine from Colombia, which created a logistical nightmare for the family.

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develTherapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develtherapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develtherapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

It's a chiropractic office, has 2 bathrooms, 4 offices and one large area for physical therapy treatments.

Although the biotech has only conducted preclinical studies so far, there are several potential advantages to nonviral therapies, including being quicker to develop and possibly eliminating the need for a lengthy monitoring period of patients after treatment.

The FDA approved a Lutetium - 177 based cancer therapy called Lutathera for the treatment of neuroendocrine tumors earlier this year, after Novartis snapped up the developer, Advanced Accelerator, at a premium.

-- To learn about EMDR Therapy: Among the hundreds of types of therapy, the treatment I found most effective and gave quickest relief and results for panic attacks, anxiety and depression, for me personally, is what the State Department of Defense uses to process vets from the battlefield (even though I'm not a solider): http://www.emdr.com/what-iTherapy: Among the hundreds of types of therapy, the treatment I found most effective and gave quickest relief and results for panic attacks, anxiety and depression, for me personally, is what the State Department of Defense uses to process vets from the battlefield (even though I'm not a solider): http://www.emdr.com/what-itherapy, the treatment I found most effective and gave quickest relief and results for panic attacks, anxiety and depression, for me personally, is what the State Department of Defense uses to process vets from the battlefield (even though I'm not a solider): http://www.emdr.com/what-is-emdr/